# Comparison of Callisphere Drug-Eluting Beads Transarterial Chemoembolization and Conventional Transarterial Chemoembolization for the treatment of Hepatocellular Carcinoma

## TL;DR

This study compares two treatments for liver cancer and finds that drug-eluting beads offer better results with fewer side effects.

## Contribution

Demonstrates that CalliSphere drug-eluting beads chemoembolization improves outcomes over conventional methods in hepatocellular carcinoma.

## Key findings

- CalliSphere DEB-TACE had a higher objective response rate (85.25%) compared to conventional TACE (70.31%).
- Patients treated with DEB-TACE had longer median survival (24.85 months) than those with conventional TACE (18.18 months).
- DEB-TACE resulted in fewer adverse reactions (4.92%) compared to conventional TACE (17.19%).

## Abstract

To compare the efficacy of CalliSphere drug-eluting beads (DEBs) and conventional (c) transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC).

We retrospectively reviewed the clinical data of 125 patients with HCC who had received treatment in Affiliated Hospital of North Sichuan Medical College from January 2018 to February 2019. Sixty-one patients underwent DEB-TACE (observation group) and 64 patients underwent cTACE (control group). The clinical efficacies, overall survivals, and incidence of postoperative adverse reactions between the two groups were compared.

The objective response rate in the observation group (85.25%) was higher than that in the control group (70.31%; P<0.05). The disease control in the observation group (96.72%) was higher than that in the control group (85.94%; P<0.05). The median survival time of the observation group (24.85 months) was significantly higher than that in the control group (18.18 months; P<0.05). The incidence of adverse reactions in the observation group (4.92%) was lower than that in the control group (17.19%, P<0.05).

In the treatment of HCC, Callisphere DEB-TACE has better efficacy and longer patient survival with fewer adverse reactions compared to cTACE.